Literature DB >> 11558289

A study of 510 carotid endarterectomies and a review of the recent carotid endarterectomy trials.

A F AbuRahma1, R S Hannay.   

Abstract

The release of several randomized trials comparing carotid endarterectomy (CEA) to other methods of stroke prevention in the early 1990s established CEA as the "gold standard" in the prevention of stroke from carotid occlusive disease. This study examines 510 of the CEAs performed by the first author at Charleston Area Medical Center in Charleston, W. Va., from 1991-99, which were part of three prospective randomized CEA trials at CAMC. All patients were observed clinically and underwent postoperative color duplex ultrasound scans at 30 days, six months, 12 months, and every year thereafter to assess the presence of recurrent stenoses. The overall perioperative stroke rate in the whole series was 2.7% (14/510). The incidence of perioperative ipsilateral stroke was 4.6% for CEA with primary closure vs. 1.9% for CEA with patching (p < 0.05). Patching using PTFE or vein patch closure had the lowest incidence of perioperative stroke rate (0.7%). Primary closure had a statistically significant higher incidence of recurrent stenoses than PTFE or vein patch closure (28% vs. 2.9%, p < 0.0001). The incidence of ipsilateral stroke and recurrent stenosis using the Hemashield patch was higher than either PTFE or vein patch closure. As the indications for CEA expand, the safety, utility, and cost-effectiveness of the procedure must be closely monitored at each institution. However, as shown in this study, CEA (using PTFE or vein patch closure) is a safe, effective, and well-established tool in the treatment of stroke in the 21st century.

Entities:  

Mesh:

Year:  2001        PMID: 11558289

Source DB:  PubMed          Journal:  W V Med J        ISSN: 0043-3284


  1 in total

1.  SONOlysis in prevention of Brain InfaRctions During Internal carotid Endarterectomy (SONOBIRDIE) trial - study protocol for a randomized controlled trial.

Authors:  Tomáš Hrbáč; David Netuka; Vladimír Beneš; Vladimír Nosáľ; Petra Kešnerová; Aleš Tomek; Táňa Fadrná; Vladimír Beneš; Jiří Fiedler; Vladimír Přibáň; Miroslav Brozman; Kateřina Langová; Roman Herzig; David Školoudík
Journal:  Trials       Date:  2017-01-17       Impact factor: 2.279

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.